Preprint / Version 1

Molecular Pathways of Protein Misfolding: How Structural Failure Drives Neurodegenerative Disorders

##article.authors##

  • Sujit Pappala Independent

DOI:

https://doi.org/10.58445/rars.3990

Keywords:

Protein Misfolding, Neurodegenerative Diseases, Alzheimer's Disease

Abstract

Proteins are essential molecules that carry out many functions within living cells, and these functions range from transmitting signals to catalyzing reactions. The proper performance of proteins within these cells relies heavily on the protein’s ability to fold into precise three-dimensional shapes. Additionally, protein’s shape determines which molecules it can bind to and how it interacts with other cellular structures. But when these proteins fail to fold correctly, they can’t perform these vital tasks, and begin forming harmful properties that accumulate and interfere with cellular health. These misfolded proteins develop the basis for many of the leading neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), and other rare prion diseases. This literature review explores the molecular pathways that direct protein folding, the biological and external factors that direct protein misfolding, and the consequences of accumulation of misfolded proteins. It examines how these misfolded proteins can disrupt cell function, how they contribute to disease progression, and why neurons are vulnerable to these changes. The paper also delves into modern diagnostic tools that can detect misfolded proteins in patients suffering with the above conditions. Additionally, this review goes into how emerging therapeutic strategies such as immunotherapy, proteostasis enhancement, artificial intelligence driven structural prediction, and others. By intertwining fundamental biochemical understandings of neurodegenerative disorders with clinical applications and relevance, this review provides a comprehensive explanation into how these structural issues arise and how they drive neurodegenerative diseases.

References

Bibliography

Chiti, F., & Dobson, C. M. (2017). Protein misfolding, amyloid formation, and human disease. Annual Review of Biochemistry, 86, 27–68. https://www.annualreviews.org/content/journals/10.1146/annurev-biochem-061516-045115

Ciechanover, A., & Kwon, Y. T. (2013). Degradation of misfolded proteins in neurodegenerative diseases. Cold Spring Harbor Perspectives in Biology, 5(9), a017863. https://pmc.ncbi.nlm.nih.gov/articles/PMC3571097/

Eisenberg, D., & Sawaya, M. R. (2017). Structural studies of amyloid fibrils. Annual Review of Biochemistry, 86, 69–95. https://www.annualreviews.org/content/journals/10.1146/annurev-biochem-061516-045104

Hetz, C., & Saxena, S. (2017). ER stress and the unfolded protein response in neurodegeneration. Nature Reviews Neurology, 13(8), 477–491. https://www.nature.com/articles/nrneurol.2017.99

Jumper, J., Evans, R., Pritzel, A., et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873), 583–589. https://www.nature.com/articles/s41586-021-03819-2

Knowles, T. P. J., Vendruscolo, M., & Dobson, C. M. (2014). The amyloid state and its association with protein misfolding diseases. Nature Reviews Molecular Cell Biology, 15(6), 384–396. https://williams.chemistry.gatech.edu/course_Information/6572_fall_2021/papers/Knowles_2014_amyloids.pdf

Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine, 8(6), 595–608. https://link.springer.com/article/10.15252/emmm.201606210

Soto, C. (2009). Unfolding the role of protein misfolding in neurodegenerative diseases. Nature Reviews Neuroscience, 10(6), 387–399. https://pmc.ncbi.nlm.nih.gov/articles/PMC2674794/

Taylor, J. P., Hardy, J., & Fischbeck, K. H. (2003). Toxic proteins in neurodegenerative disease. Nature Reviews Neuroscience, 4(1), 49–58. https://www.researchgate.net/publication/11308406_Toxic_Proteins_in_Neurodegenerative_Disease

Walsh, D. M., Selkoe, D. J., & Holtzman, D. M. (2022). Amyloid‑targeting antibodies in Alzheimer’s disease: Mechanisms and clinical outcomes. Nature Reviews Drug Discovery, 21(9), 628–644. https://pmc.ncbi.nlm.nih.gov/articles/PMC12470750/

Lashuel, H. A. (2020). Alpha‑synuclein and the pathogenesis of Parkinson’s disease. Biochemical Pharmacology, 180, 114162.

https://www.sciencedirect.com/science/article/pii/S0969996120301510?via%3Dihub

Spillantini, M. G., & Goedert, M. (2024). Tau pathology and neurodegeneration: New insights. Molecular Neurodegeneration, 19, 29. https://link.springer.com/article/10.1186/s40035-024-00429-6

Downloads

Posted

2026-07-26